Por favor, use este identificador para citar o enlazar este ítem:
DOI: 10.14670/HH-18-073
Twittear
Registro completo de metadatos
Campo DC | Valor | Lengua/Idioma |
---|---|---|
dc.contributor.author | Cuenca, L. | - |
dc.contributor.author | Gil Martinez, A.L. | - |
dc.contributor.author | Cano Fernandez, L. | - |
dc.contributor.author | Sanchez Rodrigo, C. | - |
dc.contributor.author | Estrada, C. | - |
dc.contributor.author | Fernández Villalba, Emiliano | - |
dc.contributor.author | Herrero Ezquerro, María Trinidad | - |
dc.date.accessioned | 2022-06-27T10:26:09Z | - |
dc.date.available | 2022-06-27T10:26:09Z | - |
dc.date.issued | 2019 | - |
dc.identifier.citation | Histology and Histopathology, Vol.34, nº6, (2019) | es |
dc.identifier.issn | 1699-5848 | - |
dc.identifier.issn | 0213-3911 | - |
dc.identifier.uri | http://hdl.handle.net/10201/121845 | - |
dc.description.abstract | After Alzheimer’s disease, Parkinson’s disease (PD) is the second most prevalent and incidental neurodegenerative disorder, affecting more than 2% of the population older than 65 years old. Since it was first described 200 years ago by Dr James Parkinson, great steps have been made in the understanding of the pathology. However, the cause(s) that initiates and perpetuates the neurodegenerative process is (are) still not clear. Thus, early diagnosis is not available, nor are there efficient therapies that can stop neurodegeneration. PD clinical features are defined by motor (like bradykinesia, resting tremor, gait impairment) and nonmotor symptoms (like constipation, apathy, fathigue, olfactory dysfunction, depression and cognitive decline) that get more severe as the disease advances. Neuropathological hallmarks comprise selective loss of dopaminergic neurons in the Substantia Nigra pars compacta (SNpc) and Lewy bodies (LB) in different nuclei of the nervous system. Numerous studies have shown that these pathological features are aggravated by the confluence of other contributing factors, such as a genetic component, exposure to environmental toxins, mitochondrial dysfunction, increase of oxidative stress, calcium imbalance and chronic neuroinflammation, among others. Here, we provide a summary of the actual state of PD’s pathology, the most studied molecular mechanisms, classic and novel therapeutic strategies and diagnosis methods, especially highlighting recent advances in these 200 years | es |
dc.format | application/pdf | es |
dc.format.extent | 19 | es |
dc.language | eng | es |
dc.publisher | Universidad de Murcia. Departamento de Biología Celular e Histología | es |
dc.relation | Sin financiación externa a la Universidad | es |
dc.rights | info:eu-repo/semantics/openAccess | es |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | Parkinson’s disease | es |
dc.subject | 200 years anniversary | es |
dc.subject | Neurodegeneration | es |
dc.subject | Dopamine | es |
dc.subject | Lewy bodies | es |
dc.subject.other | CDU::6 - Ciencias aplicadas::61 - Medicina::616 - Patología. Medicina clínica. Oncología | es |
dc.title | Parkinson's disease: a short story of 200 years | es |
dc.type | info:eu-repo/semantics/article | es |
dc.identifier.doi | DOI: 10.14670/HH-18-073 | - |
Aparece en las colecciones: | Vol.34, nº6 (2019) |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
Cuenca-34-573-591-2019.pdf | 1,44 MB | Adobe PDF | Visualizar/Abrir |
Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons